Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 李思先生 黃江先生 黃慈波教授 董事會設有五個董事委員會，成員組合如下： 審核委員會 李思先生 （主席） 黃江先生 黃慈波教授 董事名單與其角色和職能 中基長壽科學集團有限公司董事會（「董事會」）成員載列如下： 執行董事 閆立先生 （主席及行政總裁） 李小雙先生 非執行董事 何亦武博士 呂長勝先生 獨立非執行董事 本公告之中英文本如有任何歧義，概以英文本為準。 閆立先生 （主席） 李思先生 黃江先生 黃慈波教授 股份獎勵委員會 閆立先生 （主席） 李思先生 黃江先生 黃慈波教授 香港，二零二五年十月十七日 – 1 – 提名委員會 閆立先生 （主席） 李思先生 黃江先生 黃慈波教授 薪酬委員會 黃江先生 （主席） 李思先生 黃慈波教授 風險管理委員會 – 2 – ...

Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 執行董事辭任及行政總裁變動 中基長壽科學集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈，由於閆一帆先生（「閆先生」）及曹衆女士（「曹女士」）希望投 放更多時間於個人及其他業務承擔上，故閆先生已辭任執行董事及行政總裁，而曹 女士已辭任本公司執行董事，兩者均自二零二五年十月十七日起生效。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 閆立先生，54歲，於二零二零年十一月加入本公司擔任執行董事，並於二零二零年 十二月獲委任為董事會主席及董事會轄下提名委員會主席及於二零二一年五月獲委 任為董事會股份獎勵委員會主席。彼於二零二零年獲頒授美國格林威爾大學國際榮 譽院士，原深圳市社會組織總會副會長、原深圳市商業聯合會副會長。閆立先生在 先進醫療、生物科 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中基長壽科學集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00767 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | ...

Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 (Incorporated in Bermuda with limited liability) ) ( 於百慕達註冊成立之有限公司 (Stock Code 股份代號: 767) N O T I F I C AT I O N L E T T E R Dear Non-registered holders(Note 1) Zhong Ji Longevity Science Group Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock ...

Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 (Incorporated in Bermuda with limited liability) ( 於百慕達註冊成立之有限公司 ) (Stock Code 股份代號: 767) N O T I F I C AT I O N L E T T E R Dear Registered Shareholders, 26 September 2025 Zhong Ji Longevity Science Group Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of ...

Dividend and Financial Performance - The Company did not declare an interim dividend for the six months ended June 30, 2025, consistent with the previous year[11]. - For HY2025, the Group recorded total revenue of HK$47,973,000, an increase from HK$42,403,000 in HY2024[32]. - The Group reported a loss of HK$12,922,000 for HY2025, compared to a loss of HK$917,000 in HY2024[32]. - The longevity science business generated revenue of HK$34,253,000 but incurred a segment loss of HK$10,945,000 for HY2025[32]. - The money lending and financial advisory business had static revenue of HK$13,720,000 and a segment profit of HK$12,306,000 for HY2025[37]. - The Group's basic and diluted loss per share was HK$2.29 cents as of June 30, 2025, compared to HK$0.2 cents on June 30, 2024[33]. - The revenue from the longevity science business segment amounted to approximately HK$34,253,000 for HY2025, an increase from HK$25,180,000 in HY2024[84]. - The segment incurred a loss of approximately HK$10,945,000 in HY2025, compared to a loss of HK$4,342,000 in HY2024, primarily due to unforeseen events and operational challenges post-pandemic[88]. Business Operations and Strategy - The Company is diversifying its business and has become Asia's first one-stop health and longevity center since late 2022[12]. - The Company is focusing on expanding its longevity science business alongside its existing financial services[12]. - The Group is focusing on diversifying into promising longevity medical health businesses to enhance financial performance[26]. - The Company engaged Dongwei Law Firm to expedite the recovery of overdue loans from strategic partners, extending the service contract for an additional 36 months in August 2024[20]. - The restructuring of Tian Xing has been completed, restoring business partnerships and banking authority operations by June 2023[14]. - The Group plans to monetize portions of its loan portfolio with strategic partners Fanhua and Haier through ongoing negotiations[40]. - The Group has engaged with strategic partners to negotiate the monetization of parts of the loan portfolio, indicating ongoing market expansion efforts[42]. Loan Management and Recovery - The overdue loans from strategic partners are being managed with partial initial loan principals supplied by the Company[21]. - The strategic partner loans are being managed to recover overdue amounts, with RMB$6.7 million cash recovered from two borrowers[38]. - The recovery actions for impaired loans have entered a review assessment stage, highlighting the company's commitment to recovering outstanding amounts[46]. - The Independent Recovery Committee has successfully recovered gross proceeds from two borrower entities of four loans out of the 36 long-impaired loans, although the recovery process is still ongoing[45]. - The outstanding loans previously impaired amounted to approximately HK$1,076,000,000 as of December 31, 2019, with recovery efforts ongoing since August 2022[46]. Customer and Revenue Concentration - The top five customers accounted for approximately 51% of total revenue in HY2025, up from 33% in HY2024, with the largest customer contributing about 30% of total revenue, compared to 24% in HY2024[49]. - As of June 30, 2025, the largest customer and the top five customers accounted for 40% and 89% of the total gross loan receivables balance, respectively[49]. - The top five borrowers under the Strategic Partners Business Model accounted for approximately 20.13% of the entire other receivables of the Group as of June 30, 2025, up from 12.917% as of December 31, 2024[74]. - The top five borrowers under the Corporate and Personal Borrowers Business Model accounted for approximately 79.38% of the entire loan and interest receivables of the Group as of June 30, 2025, down from 89.19% as of December 31, 2024[82]. Financial Position and Assets - As of June 30, 2025, the Group's consolidated net assets were HK$431,540,000, up from HK$400,139,000 on December 31, 2024[33]. - As of June 30, 2025, the Group's net current assets were approximately HK$405,862,000, an increase from HK$372,047,000 as of December 31, 2024[97]. - Cash and bank balances as of June 30, 2025 were approximately HK$30,036,000, down from HK$47,842,000 as of December 31, 2024[100]. - The Group's bank and other borrowings decreased to HK$9,105,000 as of June 30, 2025, compared to HK$11,541,000 as of June 30, 2024[102]. - As of June 30, 2025, strategic partners loan assets were approximately HK$178,004,000 before impairments, with a net carrying value of approximately HK$113,422,000[74]. - The corporate and personal borrowers business loan assets were approximately HK$865,512,000 before impairments, with a net carrying value of approximately HK$228,801,000 as of June 30, 2025[82]. Share Capital and Employee Information - The total number of issued ordinary shares increased to 636,654,300 as of June 30, 2025, up from 546,529,549 as of December 31, 2024[103]. - The Group's employee count decreased to approximately 52 as of June 30, 2025, from 55 as of December 31, 2024[120]. - Employee benefits expense, excluding Directors' emoluments, was approximately HK$8.2 million in HY2025, representing an increase of about 29.8% compared to HK$6.3 million in HY2024[117]. Share Option and Award Schemes - The 2012 Share Option Scheme has 3,868,000 outstanding share options as of June 30, 2025, with an exercise period from December 31, 2023, to December 30, 2030[151]. - The 2022 Share Option Scheme allows the Board to grant options to qualifying participants, with the exercise price complying with Listing Rules[151]. - The total number of shares available for issue under the 2022 Share Option Scheme represents approximately 6.1% of the ordinary shares of the Company in issue[170]. - The Share Award Scheme was adopted on May 18, 2021, to recognize contributions and provide incentives for participants[188]. - The maximum number of restricted shares that may be awarded under the Share Award Scheme shall not exceed 38,680,000 shares, which is capped at 10% of the issued share capital of the Company[195].

Core Viewpoint - The company has signed a cooperation agreement to establish an "International Precision Medicine Center for Oncology" with Hainan Boao Super Hospital, which is expected to enhance its business development in the longevity science sector [1] Group 1: Cooperation Agreement Details - The agreement was signed on September 13, 2025, between Zhongli (Hainan) Life Science Technology Co., Ltd. and Hainan Boao Super Hospital [1] - Hainan Boao will provide the center's facilities and services, while Zhongli Hainan will manage operations and provide expert support and specialized equipment [1] Group 2: Market Outlook - The board believes that the longevity science market has significant potential, as affluent clients are increasingly willing to invest in longevity applications to improve their overall health and immune status [1] - The cooperation aligns with the company's strategic development plans in the longevity science sector, laying a solid foundation for future domestic market expansion [1] Group 3: Revenue Growth Potential - The agreement is expected to enhance the company's positioning in the longevity science diagnostics and medical services field, opening new revenue streams [1] - The board anticipates that this initiative will lead to more stable and sustainable revenue growth in the long term [1]

Core Viewpoint - The company has signed a cooperation agreement to establish an "International Precision Medicine Center for Oncology" with Hainan Boao Super Hospital, which is expected to enhance its business development in the longevity science sector [1] Group 1: Partnership Details - The indirect non-wholly owned subsidiary of the company, Zhongli (Hainan) Life Science Technology Co., Ltd., will collaborate with Hainan Boao Super Hospital to jointly operate the medical center [1] - Hainan Boao will provide the facility and services for outpatient, inpatient, examination, treatment, and surgery, while Zhongli Hainan will manage operations and provide expert support and specialized equipment [1] Group 2: Market Outlook - The board believes that the longevity science market has significant potential, as affluent clients are increasingly willing to invest in longevity science applications to enhance their overall health and immune status [1] - The cooperation agreement aligns with the company's development strategy in longevity science and is expected to solidify its foundation for expanding into the domestic market [1] Group 3: Future Growth Potential - The agreement is anticipated to improve the company's positioning in the longevity science diagnostic and medical service sectors, opening new revenue streams [1] - The board expects this initiative to contribute to more stable and sustainable revenue growth in the long term [1]

Group 1 - The company, Zhongji Changshou Science (00767.HK), has signed a cooperation agreement with Hainan Boao Super Hospital to establish an "International Precision Medicine Center for Oncology" [1] - Hainan Boao will provide the center's facilities and services, while Zhongji Changshou will manage operations and provide expert support and specialized equipment [1] - The Boao Super Hospital is recognized as a pioneer in China's medical field, leveraging special policies to utilize advanced foreign medical technologies and services [1] Group 2 - The board believes that the market for longevity science is promising, as affluent clients are increasingly willing to invest in longevity applications to enhance their health and vitality [2] - The cooperation agreement aligns with the company's strategy for developing longevity science, laying a solid foundation for future business expansion in the domestic market [2] - The agreement is expected to enhance the company's positioning in the longevity science diagnostic and medical service sectors, creating new revenue streams for stable and sustainable growth [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 自願公告 合作協議 本公告由中基長壽科學集團有限公司（「本公司」，連同其附屬公司，「本集團」）自願 作出。 合作協議 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年九月十三日，本公司之 間接非全資附屬公司中驪（海南）生命科學技術有限公司（「中驪海南」）與海南博鼇超 級醫院有限公司（「海南博鼇」）簽署合作協議（「合作協議」），據此，中驪海南與海南 博鼇雙方共同建立「國際腫瘤精準醫學中心」（「醫學中心」），海南博鼇負責提供中心 的場地及提供「1+X」平台的服務功能，包括但不限於：門診、住院、檢查、治療、 手術等，中驪海南負責中心的營運並提供專家及專科技術和專科設備支援，雙方共 同為患者開展診療活動及各種科研項目。 – 1 – 關於海 ...